

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet	1	of	3
-------	---	----	---

Complete if Known **10/527426**

Application Number	Based on PCT/JP2003/011511
Filing Date	Intl. filing 09 SEPTEMBER 2003
First Named Inventor	Yu MOMOSE
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3094 USOP

## U. S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code <sup>2</sup> *Number <sup>4</sup> *Kind Code <sup>3</sup> (if known)	MM-DD-YYYY			
/SL/	A4	WO 02/053547 A1-Abstract	07/11/2002	Takeda Chemical Industries		
↓	A5	WO 02/076959 A1-Abstract	10/03/2002	Takeda Chemical Industries		
	A6	WO 01/17994 A1	03/15/2001	Glaxo Group Limited		
	A7	WO 01/00603 A1	01/04/2001	Glaxo Group Limited		
	A8	GB 2 110 211 A	06/15/1983	F. Hoffman-LaRoche and Co. AG		
	A9	WO 01/16111 A2	03/08/2001	Eli Lilly and Company		

**Examiner  
Signature**

/Sun Jae Loewe/

Date Considered

08/06/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind's code of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

*(Use as many sheets as necessary)*

Complete if Known **10/527426**

Application Number	Based on PCT/JP2003/011511
Filing Date	Intl. filing 09 SEPTEMBER 2003
First Named Inventor	Yu MOMOSE
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3094 USOP

Sheet	2	of	3
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
/S/	A10	WO 96/13264	05/09/1996	Eli Lilly and Company		
↓	A11	JP 63159373-Abstract	07/02/1988	Nissan Chemical Ind Ltd		
	A12	WO 03/015774 A1	02/27/2003	Astrazeneca AB		
	A13	WO 03/000685-Abstract	01/03/2003	Takeda Chemical Industries		
	A14	WO 00/64876	11/02/2000	Aventis Pharmaceuticals Products		
	A15	WO 01/38325 A1	05/31/2001	Takeda Chemical Industries		

Examiner Signature	/Sun Jae Loewe/	Date Considered	08/06/2007
-----------------------	-----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

10/527426

Sheet 3

of

3

Application Number

Based on PCT/JP2003/011511

Filing Date

Intl. Filing 09 SEPTEMBER 2003

First Named Inventor

Yu Momose

Art Unit

tba

Examiner Name

tba

Attorney Docket Number

3094 USOP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/SL/	A16	E. WINKELMANN, et al., "Chemotherapeutically Active Nitro Compounds", <i>Arzneim-Forsch./Drug Res.</i> 28(I), Heft 5, (1978), pp. 739-749	
	A17	E. WINKELMANN, et al., "Chemotherapeutically Active Nitro Compounds", <i>Arzneim-Forsch./Drug Res.</i> 28(I), Heft 3, (1978), pp. 351-366	
	A18	YU MOMOSE, et al., "Novel 5-Substituted-1H-tetrazole Derivatives as Potent Glucose and Lipid Lowering Agents", <i>Chem. Pharm. Bull.</i> , (2002), pp. 100-111, Vol. 50, No. 1	
	A19	JOHN J. BALDWIN, et al., "Beta 1-Selective Adrenoceptor Antagonists: Examples of the 2-[4-[3-(Substituted amino)-2-hydroxypropoxy]phenyl]imidazole Class. 2", <i>Journal of Medicinal Chemistry</i> , (1986), pp. 1065-1080, Vol. 29, No. 6	
↓	A20	YU MOMOSE, et al., "Novel 5-Substituted 2,4-Thiazolidinedione and 2,4-Oxazolidinedione Derivatives as Insuline Sensitizers with Antidiabetic Activities", <i>J. Med. chem.</i> , (2002), pp. 1518-1534, Vol. 45, No. 7	

Examiner  
Signature

/Sun Jae Loewe/

Date

Considered

08/06/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.